Efficacy and tolerability of the single-pill combination of aliskiren 300 mg/amlodipine 10 mg in hypertensive patients not controlled by olmesartan 40 mg/amlodipine 10 mg

References

• Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007;28:1462-536
   PubMed Web of Science ®Google Scholar
• Danaei G, Finucane MM, Lin JK, et al. National, regional, and global trends in systolic blood pressure since 1980: systematic analysis of health examination surveys and epidemiological studies with 786 country-years and 5.4 million participants. Lancet 2011;377:568-77
   PubMed Web of Science ®Google Scholar
• Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351:1755-62
   PubMed Web of Science ®Google Scholar
• Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-71
   PubMed Web of Science ®Google Scholar
• Deutsche Hypertonie Gesellschaft – Deutsche Hochdruckliga e.V. (DHL). S2 Guideline: Treatment of Arterial Hypertension. Bonn, 2008. Available at: http://www.awmf.org/uploads/tx_szleitlinien/046-001_S2_Behandlung_der_arteriellen_Hypertonie_06-2008_06-2013.pdf [Last accessed 27 October 2011]
   Google Scholar
• Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010;55:399-407
   PubMed Web of Science ®Google Scholar
• Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med 2007;120:713-19
   PubMed Web of Science ®Google Scholar
• Amlodipinbesilat-Sandoz (Manufacturer: Sandoz Pharmaceuticals GmbH, Holzkirchen). Fachinformation (Prescribing Information). Updated July 2010. Available at: www.fachinfo.de [Last accessed 22 July 2011]
   Google Scholar
• Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995;50:560-86
   PubMed Web of Science ®Google Scholar
• Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther 2008;30:587-604
   PubMed Web of Science ®Google Scholar
• Barrios V, Brommer P, Haag U, et al. Olmesartan medoxomil plus amlodipine increases efficacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009;29:427-39
   PubMed Web of Science ®Google Scholar
• Volpe M, Brommer P, Haag U, et al. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig 2009;29:11-25
   PubMed Web of Science ®Google Scholar
• Sanford M, Keam SJ. Olmesartan medoxomil/amlodipine. Drugs 2009;69:717-29
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Olmesartan/amlodipine fixed combination.Daiichi Sankyo, Azor (TM) full prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022100s002lbl.pdf [Last accessed 28 August 2011]
   Google Scholar
• Reboldi G, Gentile G, Angeli F, et al. Pharmacokinetic, pharmacodynamic and clinical evaluation of aliskiren for hypertension treatment. Expert Opin Drug Metab Toxicol 2011;7:115-28
   PubMed Web of Science ®Google Scholar
• Duggan ST, Chwieduk CM, Curran MP. Aliskiren: a review of its use as monotherapy and as combination therapy in the management of hypertension. Drugs 2010;70:2011-49
   PubMed Web of Science ®Google Scholar
• Billecke SS, Marcovitz PA. Aliskiren/amlodipine combination for the treatment of hypertension. Drugs Today (Barc) 2011;47:403-17
   PubMed Web of Science ®Google Scholar
• Brown MJ, McInnes GT, Papst CC, et al. Aliskiren and the calcium channel blocker amlodipine combination as an initial treatment strategy for hypertension control (ACCELERATE): a randomised, parallel-group trial. Lancet 2011;377:312-20
   PubMed Web of Science ®Google Scholar
• Black H, Weinberger M, Purkayastha D, et al. Combination aliskiren plus amlodipine provides greater reductions in clinic and 24-hour ambulatory blood pressures than amlodipine alone in African Americans with stage 2 hypertension [Poster 5.187]. J Hypertens 2010;28(e-Suppl A):e103
   Google Scholar
• Palatini P, Jung W, Shlyakhto E, et al. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010;24:93-103
   PubMed Web of Science ®Google Scholar
• Smilde J. A comparison of amlodipine and felodipine extended release in the treatment of hypertension at steady state and after two missed doses. Curr Ther Res 1997;58:141-53
   Web of Science ®Google Scholar
• Burnier M, Brede Y, Lowy A. Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril. Int J Clin Pract 2011;65:127-33
   PubMed Web of Science ®Google Scholar
• Lowy A, Munk VC, Ong SH, et al. Effects on blood pressure and cardiovascular risk of variations in patients' adherence to prescribed antihypertensive drugs: role of duration of drug action. Int J Clin Pract 2011;65:41-53
   PubMed Web of Science ®Google Scholar
• Düsing R, Baschiera F, Baek I, et al. Aliskiren provides more prolonged reductions in 24-hour mean ambulatory blood pressure during treatment withdrawal than telmisartan [Poster 15.393]. Presented at the European Society of Hypertension Meeting in Milan 17–20 June 2012
   Google Scholar
• Clinical Trials Database. Rasilamlo Factorial Study SPA 2305. Available at: http://clinicaltrials.gov/ct2/show/results/NCT00739973?term=NCT00739973&rank=1&sect=Xr015#outcome22 [Last accessed 27 October 2011]
   Google Scholar
• Pfeiffer D, Rennie N, Papst C, et al. Efficacy and Tolerability of Aliskiren/Amlodipine Single-Pill Combinations in Hypertensive Patients who did not Respond Fully to Amlodipine Monotherapy: An 8-Week, Randomized, Double-Blind Study (Poster 332). High Blood Pressure Research 2011 Sessions (AHA Meeting), Orlando, FL, USA, 20–24 September 2011
   Google Scholar
• Glorioso N, Thomas M, Patel S, et al. Antihypertensive Efficacy and Tolerability of Aliskiren/Amlodipine Single-Pill Combinations in Hypertensive Patients with an Inadequate Response to Aliskiren Monotherapy: An 8-Week, Randomized, Double-Blind Study (Poster 328). High Blood Pressure Research 2011 Sessions (AHA Meeting), Orlando, FL, USA, 20–24 September 2011
   Google Scholar
• European Medicines Agency (EMA). Rasilmalo (Aliskiren/Amlodipine, EMEA/H/C/002073). Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002073/WC500107200.pdf [Last accessed 6 October 2011]
   Google Scholar
• Lacourciere Y, Taddei S, Konis G, et al. Aliskiren/amlodipine/hydrochlorothiazide triple combination provides superior blood pressure reductions compared to component dual combinations in patients with moderate-to-severe hypertension (Poster PS2/TUE/9). 23rd Scientific Meeting of the International Society of Hypertension, 26–30 September 2010, Vancouver, Canada
   Google Scholar
• Novartis Pharma. Full prescribing Information Amturnide. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/amturnide.pdf [Last accessed 8 August 2011]
   Google Scholar
• Pickering TG, Hall JE, Appel LJ, et al. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals: Part 1: Blood Pressure Measurement in Humans: A Statement for Professionals From the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension 2005;45:142-61
   PubMed Web of Science ®Google Scholar
• Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13
   PubMed Web of Science ®Google Scholar
• Krone W, Hanefeld M, Meyer HF, et al. Comparative efficacy and safety of aliskiren and irbesartan in patients with hypertension and metabolic syndrome. J Hum Hypertens 2010;25:186-95
   PubMed Web of Science ®Google Scholar
• Gradman AH, Schmieder RE, Lins RL, et al. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 2005;111:1012-18
   PubMed Web of Science ®Google Scholar
• Stanton A, Jensen C, Nussberger J, et al. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003;42:1137-43
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMEA). Rasilez. Assessment Report: Scientific Discussion. Available at: http://www.ema.europa.eu/humandocs/Humans/EPAR/rasilez/rasilez.htm [Last accessed 30 August 2010]
   Google Scholar
• Pool JL, Schmieder RE, Azizi M, et al. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan. Am J Hypertens 2007;20:11-20
   PubMed Web of Science ®Google Scholar
• Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007;370:221-9
   PubMed Web of Science ®Google Scholar
• Braun N, Ulmer HJ, Ansari A, et al. Efficacy and safety of the single pill combination of amlodipine 10 mg plus valsartan 160 mg in hypertensive patients not controlled by amlodipine 10 mg plus olmesartan 20 mg in free combination. Curr Med Res Opin 2009;25:421-30
   PubMed Web of Science ®Google Scholar
• Brachmann J, Ansari A, Mahla G, et al. Effective and safe reduction of blood pressure with the combination of amlodipine 5 mg and valsartan 160 mg in hypertensive patients not controlled by calcium channel blocker monotherapy. Adv Ther 2008;25:399-411
   PubMed Web of Science ®Google Scholar
• Schweizer J, Hilsmann U, Neumann G, et al. Efficacy and safety of valsartan 160/HCTZ 25 mg in fixed combination in hypertensive patients not controlled by candesartan 32 mg plus HCTZ 25 mg in free combination. Curr Med Res Opin 2007;23:2877-85
   PubMed Web of Science ®Google Scholar
• Schweizer J, Ulmer HJ, Benduhn H, et al. Efficacy and tolerability of aliskiren 300 mg/hydrochlorothiazide 25 mg (+/− amlodipine 5 mg) in hypertensive patients not controlled by candesartan 32 mg plus HCT 25 mg. Curr Med Res Opin 2011;27:131-40
   PubMed Web of Science ®Google Scholar
• Weir MR, Hsueh WA, Nesbitt SD, et al. A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil +/- hydrochlorothiazide. J Clin Hypertens (Greenwich) 2011;13:404-12
   PubMed Web of Science ®Google Scholar
• Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet 2004;363:2049-51
   PubMed Web of Science ®Google Scholar